Rolf Jautelat

USPTO Granted Patents = 33 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 19)

Average Co-Inventor Count = 8.1

ph-index = 11

Forward Citations = 324(Granted Patents)

Location History:

Berlin, DE (2005 - 2013)
Haan, DE (2013 - 2024)

Company Filing History:

10 out of 721

Bayer Intellectual Property Gmbh

patents

7 out of 378

Bayer Pharma Aktiengesellschaft

patents

6 out of 1,384

Schering Aktiengesellschaft

Bayer Schering Pharma Ag

patents

Years Active: 2005-2024

where 'Filed Patents' based on already Granted Patents

33 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12064429 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2024-08-20),

2. 11439642 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2022-09-13),

3. 10736896 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2020-08-11),

4. 10662185 - Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use (2020-05-26),

5. 10052312 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2018-08-21),

6. 9993476 - Substituted 5-flouro-1H-pyrazolopyridines and their use (2018-06-12),

7. 9624214 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2017-04-18),

8. 9309239 - Substituted 6-fluoro-1H-pyrazolo[4,3-b]pyridines and use thereof (2016-04-12),

9. 9284317 - Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors (2016-03-15),

10. 9266885 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2016-02-23),

11. 9255100 - Substituted imidazopyridazines (2016-02-09),

12. 9212184 - 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors (2015-12-15),

13. 9199999 - Substituted imidazopyrazines (2015-12-01),

14. 9126998 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2015-09-08),

15. 8946215 - Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2015-02-03),

Title: Rolf Jautelat: Innovator in Medicinal Chemistry

Introduction

Rolf Jautelat, a distinguished inventor based in Haan, Germany, has made significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 33 patents, Jautelat has focused primarily on novel compounds that play crucial roles in the treatment and prevention of various diseases.

Latest Patents

Among his latest patents are the innovative substituted 5-fluoro-1H-pyrazolopyridines. These novel compounds are designed for their use in the treatment and prophylaxis of diseases, particularly cardiovascular disorders. The patent details not only the preparation processes of these compounds but also emphasizes their potential applications in developing effective medicaments.

Career Highlights

Throughout his career, Rolf Jautelat has been associated with prominent companies such as Bayer Intellectual Property GmbH and Bayer Pharma Aktiengesellschaft. His work in these organizations has allowed him to advance his research and focus on pivotal innovations in medicinal chemistry.

Collaborations

Jautelat has collaborated with esteemed colleagues including Johannes-Peter Stasch and Gorden Redlich. These partnerships have fostered a rich environment for innovation, contributing to the development of groundbreaking medicinal compounds and their applications in healthcare.

Conclusion

Rolf Jautelat's dedication to advancing medicinal chemistry through his inventions and patents marks him as a notable figure in the industry. His innovative work, especially in the realm of cardiovascular treatments, continues to inspire future research and development in the field.

This text is generated by artificial intelligence and may not be accurate.